TY - JOUR
T1 - Ushering in the study and treatment of preclinical Alzheimer disease
AU - Langbaum, Jessica B.
AU - Fleisher, Adam S.
AU - Chen, Kewei
AU - Ayutyanont, Napatkamon
AU - Lopera, Francisco
AU - Quiroz, Yakeel T.
AU - Caselli, Richard J.
AU - Tariot, Pierre N.
AU - Reiman, Eric M.
N1 - Funding Information:
This article was supported by grants from the National Institute on Aging (R01AG031581 and P30AG19610 to E. M. Reiman, and RF1AG041705 to E. M. Reiman, P. N. Tariot and F. Lopera), the National Institute of Neurological Disorders and Stroke (F31-NS078786 to Y. T. Quiroz), Colciencias (1115-493-26133, 1115-545-31651 and 1115-519-29028 to F. Lopera), the Banner Alzheimer’s Foundation, and the state of Arizona. The authors acknowledge research support from the Geoffrey Benne Gives Back Alzheimer’s Initiative (to J. B. Langbaum), the Anonymous Foundation (to E. M. Reiman) and the Nomis Foundations (to P. N. Tariot, F. Lopera and E. M. Reiman). We thank H. Protas for her assistance in creating the figures prior to submission, and N. Fox, C. Rowe, M. Weiner and their colleagues for permission to use their images in Figure 2. We thank our valued research participants for their invaluable dedication and inspiration.
PY - 2013/7
Y1 - 2013/7
N2 - Researchers have begun to characterize the subtle biological and cognitive processes that precede the clinical onset of Alzheimer disease (AD), and to set the stage for accelerated evaluation of experimental treatments to delay the onset, reduce the risk of, or completely prevent clinical decline. In this Review, we provide an overview of the experimental strategies, and brain imaging and cerebrospinal fluid biomarker measures that are used in early detection and tracking of AD, highlighting at-risk individuals who could be suitable for preclinical monitoring. We discuss how advances in the field have contributed to reconceptualization of AD as a sequence of biological changes that occur during progression from preclinical AD, to mild cognitive impairment and finally dementia, and we review recently proposed research criteria for preclinical AD. Advances in the study of preclinical AD have driven the recognition that efficacy of at least some AD therapies may depend on initiation of treatment before clinical manifestation of disease, leading to a new era of AD prevention research.
AB - Researchers have begun to characterize the subtle biological and cognitive processes that precede the clinical onset of Alzheimer disease (AD), and to set the stage for accelerated evaluation of experimental treatments to delay the onset, reduce the risk of, or completely prevent clinical decline. In this Review, we provide an overview of the experimental strategies, and brain imaging and cerebrospinal fluid biomarker measures that are used in early detection and tracking of AD, highlighting at-risk individuals who could be suitable for preclinical monitoring. We discuss how advances in the field have contributed to reconceptualization of AD as a sequence of biological changes that occur during progression from preclinical AD, to mild cognitive impairment and finally dementia, and we review recently proposed research criteria for preclinical AD. Advances in the study of preclinical AD have driven the recognition that efficacy of at least some AD therapies may depend on initiation of treatment before clinical manifestation of disease, leading to a new era of AD prevention research.
UR - http://www.scopus.com/inward/record.url?scp=84881478550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881478550&partnerID=8YFLogxK
U2 - 10.1038/nrneurol.2013.107
DO - 10.1038/nrneurol.2013.107
M3 - Review article
C2 - 23752908
AN - SCOPUS:84881478550
SN - 1759-4758
VL - 9
SP - 371
EP - 381
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
IS - 7
ER -